NCT05868525RecruitingPhase 4
Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).
Pilot, Non-masked, Randomized Clinical Trial for Evaluation of Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).
Source: ClinicalTrials.gov · Last updated 30 Jan 2026
Brief summary (registry, in English)
The goal of this clinical trial is to compare difference between Aspirin 81 mg and Aspirin 325 mg in preventing strokes in patients with head and neck vessels injury. The main questions it aims to answer are: * If Aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessels injury is not lower than and Aspirin 325 mg. * If rate of hemorrhagic complications in patients with head and neck vessels injury taking Aspirin 81 mg is not higher than patients that take Aspirin 325 mg.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 98 (estimated)
- First submitted
- 1 May 2023
- Start date
- 23 Aug 2023
- Primary completion date
- Dec 2026
- Lead sponsor
- Loma Linda University
- Diseases
- Stroke
- NCT number
- NCT05868525
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 98
- From 23 Aug 2023 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with acute spinal trauma that needs surgical intervention
Other illness
- Presence of any contraindication or history of allergy to Aspirin
- Patient with the diagnosis of acute stroke at the time of BCVI diagnosis matching the injured vessel territory on imaging
Lab values
- Patients who are on other Anti-Platelets aside from Aspirin when BCVI diagnosed
Age
- Age \<18
Other
- Pregnant women
- No enteral route access for Aspirin administration
- Patients who are on Heparin drip or other full dose anticoagulation when BCVI diagnosed
- Patients with BCVI grade 5 injury based on Biffl classification
Who the study is looking for
- Age ≥18
- All patients with blunt cerebrovascular injury are diagnosed by computed tomography angiography (CTA) upon admission
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Loma Linda University Medical Center Coordinator of this site? Confirm its status | Loma Linda | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.